Injured by Vioxx? Lawsuit and Litigation Information from Leading Attorneys

Send to Friend | Bookmark | Live Chat

On September 30, 2004, Merck & Co. issued a worldwide recall of the blockbuster arthritis drug Vioxx from the market because of data from a clinical trial that found an increased risk of heart attacks and strokes among patients.

Vioxx has also been linked to Stevens Johnson Syndrome and Toxic Epidermal Necrolysis, which are severe life-threatening skin reactions.

Update: Schmidt & Clark is no longer accepting Vioxx cases.

What is Vioxx?

Vioxx is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Vioxx works by reducing substances in the body that cause inflammation, pain, and fever. Vioxx is used to reduce pain, inflammation, and stiffness caused by osteoarthritis and adult rheumatoid arthritis. Vioxx is also used to treat painful menstruation.

Vioxx Side Effects

As with all pharmaceuticals, Vioxx comes with its list of side effects. In fact, the side effects that have been linked to Vioxx include, heart attacks, strokes, Stevens Johnson Syndrome, and Toxic Epidermal Necrolysis

Vioxx Side Effects & Lawsuit News (National)

The Case For (and Against) Big Pharma - Washington Post Resize Text Big pharma needs a miracle drug. The major drug makers are so beaten down that in some instances dividend yields, rather than the next blockbuster drug in the pipeline, are what are propping up the stocks. Take Pfizer (symbol PFE ). At ... Weitz & Luxenberg P.C. Secures $423 Million Settlement in Groundwater ... - Forbes Weitz & Luxenberg P.C. (www.weitzlux.com) has secured a landmark settlement against some of the country's biggest oil companies, which have agreed to pay $423 million in a suit involving the contamination of 153 public water systems nationally. Of ... Will There Be Time for Subprime Crime? - The Epoch Times NEW YORK?There is a time in the life of every writer when you find yourself fearing that you have become like a robo-call phone machine?repeating the same message over and over and with diminishing results. That's how I felt after 8 months of ... HealthCore building a better drug monitoring mousetrap - New Castle Business Ledger A company that got its start a dozen years ago as a unit of Blue Cross Blue Shield of Delaware is poised to play a lead role in assessing the safety of drugs. Now a part of the nation's largest Blue Cross Blue Shield organization, HealthCore will ... Some diets need a boost; People don't know all they should about ... - Owen Sound Sun Times When I first started to study nutrition in 1970 I was doing considerable business travel in the United States. I was appalled at the lack of nutrition in the American diet. I was content to be a Canadian with a better focus on "foods that schmeck ... Ibuprofen May Cut Alzheimer's Risk - WebMD May 5, 2008 -- The long-term use of ibuprofen and possibly other nonsteroidal anti-inflammatory pain relievers may help protect against Alzheimer's disease, but it is still not clear if the risks outweigh the potential benefits. Use of ibuprofen pain ... Bextra trial delay doesn't sit well with plaintiff - New London Day The woman whose case against Pfizer Inc. over the death of her husband was expected to set the tone for Bextra lawsuits everywhere has not yet received a settlement proposal, her daughter said this week. The Wall Street Journal reported Monday that ... Refer to a friend - PR Inside www.weitzlux.com - Weitz & Luxenberg P.C. (www.weitzlux.com) has secured a landmark settlement against some of the country's biggest oil companies, which have agreed to pay $423 million in a suit involving the contamination of 153 public water ... The FDA scale-up: good for big pharma or not? - Genetic Engineering News Fact: the FDA relies on user fees since the 1990s with the goal of speeding up drug approvals, meaning it is severely underfunded by the federal government and has not been able to fulfill it's mission based on that alone... NOW the FDA wants to fill ... More on Subgroup Analyses in Clinical Trials - New England Journal of Medicine To the Editor: With regard to the article by Wang et al. (Nov. 22 issue), it is increasingly recognized that subgroup analyses in clinical trials are sometimes misused and require appropriate presentation and cautious interpretation. 1 , 2 However ...